Eli Lilly Challenges EMA Decision on Alzheimer’s Drug ApprovalEli Lilly seeks reexamination of its Alzheimer's drug, Keysunra, after EMA denied approval due to brain swelling concerns.
Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy?Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side EffectsEli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug ShowdownEli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Must-Reads
1
Arrest warrants issued for 48 suspects brought from Cambodia
LATEST
2
S. Korea's exports down 7.8% in first 20 days of Oct.
LATEST
3
S. Korean man found dead in Cambodia: foreign ministry
LATEST
4
Remains of late S. Korean student tortured to death in Cambodia arrive home
LATEST
5
Trump expects 'fantastic' trade deal with China, notes 'fair' deals with S. Korea, Japan, EU
Hot Topics